Generate Biomedicines, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael T. Nally
- Full Time Employees
- 312
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 101 South Street Somerville MA United States 02143
- IPO Date
- Feb 27, 2026
- CIK
- 0002100782
- Website
- generatebiomedicines.com
- Similar Companies
- Business
- Generate:Biomedicines, Inc. conducts therapeutics design and development using computational, AI-driven biology to generate protein therapeutics across multiple disease areas. Core activities center on generative biology to identify, design, validate, and advance protein-based drug candidates from discovery through early clinical evaluation; it licenses AI-assisted platform capabilities, collaborates with pharmaceutical partners, and advances its own proprietary programs into clinical testing. Primary offerings include Generative Biology platform services; discovery and optimization of de novo protein therapeutics; target identification and validation; protein engineering and design for enhanced efficacy, safety, and manufacturability; in vitro and in vivo preclinical assessment; translational and early-phase clinical development support; strategic collaborations and licensing of its AI-driven platform and pipeline assets. The company focuses on immunology, infectious disease, and oncology pipelines, with a portfolio that includes computationally engineered monoclonal antibodies and other protein modalities. Geographic operations are centered in the United States, with headquarters in Somerville, Massachusetts, and facilities in Boynton Yards and Andover; it also engages with global partners for development, manufacturing, and clinical execution. Founded in 2018, Generate:Biomedicines operates as a biotechnology company leveraging its proprietary platform to generate and optimize novel protein therapeutics, pursuing partnerships and licensing as a route to product development and commercialization. Subsidiaries or affiliate arrangements are employed to support collaboration, development, and scale-up activities in conjunction with major pharma collaborators. The latest major changes include high-profile collaborations with global pharmaceutical companies to discover and develop protein therapeutics using the Generate Platform, advancement of multiple pipeline programs into clinical testing, and the ongoing expansion of its protein design and validation infrastructure in response to strategic partnerships and funding rounds.
Company News
Generate Biomedicines to Participate in November Investor Conferences
Banque Pictet & Cie SA Buys New Position in Generate Biomedicines Inc $GENB
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Generate Biomedicines: The Dosing Interval Is The Moat, Not The Algorithm
Contrasting Oramed Pharmaceuticals (NASDAQ:ORMP) and Generate Biomedicines (NASDAQ:GENB)
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer
Squarepoint Ops LLC Makes New $530,000 Investment in Generate Biomedicines Inc $GENB
Generate Biomedicines, Inc. (GENB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Generate Biomedicines Inc. to Participate in September Investor Conferences
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Generate Biomedicines stock jumps as post-IPO lock-up set to expire
Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
This Is Nvidia CEO Jensen Huang's Favorite Biotech Stock -- and You've Probably Never Heard of It
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It?
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts
A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Generate Biomedicines Inc’s Quiet Period To End on April 8th (NASDAQ:GENB)